Articles

  • 4 days ago | rs.bloombergadria.com | Phoebe Sedgman

    Podeli vest WhatsApp Viber Link copied Copy link Kompanije 02. jun 2025, 19:00 Sanofi je pristao da kupi kompaniju Blueprint Medicines Corp. za najmanje 9,1 milijardu dolara, i ovim francuski proizvođač lekova dodatno širi svoje prisustvo u oblasti retkih imunoloških bolesti. Sanofi će platiti 129 dolara po akciji u gotovini za američku biotehnološku firmu, navodi se u saopštenju.

  • 4 days ago | news.bloomberglaw.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong

    Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.

  • 4 days ago | bloomberglinea.com.br | Phoebe Sedgman |Amber Tong |Ashleigh Furlong |Seong Joon Cho

    Bloomberg — A Sanofi concordou em comprar a Blueprint por pelo menos US$ 9,1 bilhões, à medida que a farmacêutica francesa se expande ainda mais em doenças imunológicas raras. A Sanofi pagará US$ 129 por ação pela biotecnologia americana, informou em um comunicado. Isso representa um prêmio de 27% sobre o preço de fechamento da Blueprint na sexta-feira.

  • 4 days ago | news.bloombergtax.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong

    Sanofi SA agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker further expands its rare immunological disease portfolio. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. Sanofi has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.

  • 4 days ago | bloomberg.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong

    Laboratory research. Photographer: SeongJoon Cho/Bloomberg(Bloomberg) -- Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
835
Tweets
4K
DMs Open
No
Phoebe Sedgman
Phoebe Sedgman @PhoebeSedge
13 Oct 23

When Kenny Ives took over as boss of the trading arm of one of China’s top miners, his model was clear: “23 years at Glencore, and I loved it. So why would I do it differently?” https://t.co/xBd90AAe9J

Phoebe Sedgman
Phoebe Sedgman @PhoebeSedge
7 Sep 23

https://t.co/jITHlZs9U8

Phoebe Sedgman
Phoebe Sedgman @PhoebeSedge
18 Aug 23

RT @crampell: Ozempic & Wegovy are tilting scales of Denmark’s economy Danish drugmaker’s US sales have been so strong it's had to convert…